Empagliflozin
6
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
67%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
Antidiabetic Drugs for Steatotic Liver Disease
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels